Drug intelligence / Profile preview

recoflavone

Development stage: Phase 3
Lead developer: GL Pharm Tech
Modality: Small Molecules
Administration: Oral, Ophthalmic

Overview

Recoflavone is a synthetic small molecule derivative of eupatillen, classified as a flavone derivative. It exhibits antioxidant and anti-inflammatory properties and has been investigated primarily for the treatment of gastritis (including acute and chronic forms) and dry eye syndrome. Its mechanism of action includes inhibition of NF-kappa B, antioxidant activity, calcium channel agonism, and leukotriene inhibition. The drug was developed by Dong-A Pharmaceutical (now Dong-A ST), with clinical trials reaching phase III for gastritis and phase II for dry eye disease. Development for Crohn's disease and ulcerative colitis was discontinued[1][3][4][7].

Brand names: Recoflavone
Other names: recoflavone

Targets

NFKB1 (NF-κB1)

Beyond the preview

Go deeper on recoflavone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recoflavone.

Explore the full profile